Geneos Wealth Management Inc. Has $6.54 Million Stock Position in Insulet Corporation $PODD

Geneos Wealth Management Inc. cut its holdings in Insulet Corporation (NASDAQ:PODD) by 13.2% during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 31,174 shares of the medical instruments supplier’s stock after selling 4,750 shares during the quarter. Geneos Wealth Management Inc.’s holdings in Insulet were worth $6,542,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of PODD. Larson Financial Group LLC raised its position in Insulet by 114.6% in the fourth quarter. Larson Financial Group LLC now owns 88 shares of the medical instruments supplier’s stock valued at $25,000 after purchasing an additional 47 shares during the last quarter. University of Texas Texas AM Investment Management Co. bought a new stake in shares of Insulet during the fourth quarter worth about $26,000. Elyxium Wealth LLC acquired a new position in shares of Insulet in the fourth quarter valued at approximately $28,000. DV Equities LLC bought a new position in shares of Insulet during the fourth quarter valued at $28,000. Finally, MV Capital Management Inc. bought a new position in shares of Insulet during the fourth quarter valued at $29,000.

Insulet Stock Up 3.2%

Shares of NASDAQ PODD opened at $164.43 on Friday. The company has a quick ratio of 1.81, a current ratio of 2.49 and a debt-to-equity ratio of 0.71. The firm has a market cap of $11.39 billion, a PE ratio of 38.24, a P/E/G ratio of 1.11 and a beta of 1.11. The company’s fifty day simple moving average is $152.81 and its 200 day simple moving average is $207.20. Insulet Corporation has a 12-month low of $138.79 and a 12-month high of $354.88.

Insulet (NASDAQ:PODD) last posted its quarterly earnings results on Wednesday, May 6th. The medical instruments supplier reported $1.42 earnings per share for the quarter, beating the consensus estimate of $1.19 by $0.23. Insulet had a net margin of 10.44% and a return on equity of 26.87%. The firm had revenue of $761.70 million during the quarter, compared to the consensus estimate of $729.89 million. During the same period in the previous year, the firm posted $1.02 earnings per share. The business’s revenue was up 33.9% compared to the same quarter last year. Insulet has set its FY 2026 guidance at 6.210- EPS. As a group, sell-side analysts forecast that Insulet Corporation will post 6.45 earnings per share for the current fiscal year.

Trending Headlines about Insulet

Here are the key news stories impacting Insulet this week:

• Neutral Sentiment: Multiple law firms issued reminders and investor alerts about a securities class action against Insulet, with lead-plaintiff deadlines set for August 31, 2026. These notices generally keep the stock in the spotlight but do not by themselves change the underlying case. Article link
• Neutral Sentiment: Another law firm announced that a class action lawsuit has been filed against Insulet and certain officers on behalf of investors who bought shares during the alleged class period, reinforcing concerns about legal overhang for the company. Article link
• Neutral Sentiment: Prior reporting cited allegations that two Omnipod corrections may have exposed broader quality-control issues and contributed to a sharp earlier selloff, which helps explain why litigation-related headlines remain a focus for traders. Article link

Analyst Ratings Changes

Several analysts recently weighed in on the stock. William Blair began coverage on shares of Insulet in a research note on Wednesday, May 20th. They issued an “outperform” rating on the stock. Piper Sandler cut their target price on Insulet from $360.00 to $210.00 in a report on Wednesday, May 6th. Deutsche Bank Aktiengesellschaft began coverage on Insulet in a research report on Tuesday, June 23rd. They issued a “buy” rating and a $190.00 price target on the stock. Citigroup increased their price target on Insulet from $165.00 to $172.00 and gave the company a “neutral” rating in a research note on Wednesday, July 8th. Finally, Oppenheimer lowered their price objective on Insulet from $300.00 to $210.00 and set an “outperform” rating for the company in a research report on Thursday, May 7th. Twenty-two investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $235.25.

Insider Buying and Selling

In other news, Director Timothy C. Stonesifer purchased 2,790 shares of the company’s stock in a transaction that occurred on Wednesday, June 3rd. The shares were acquired at an average cost of $143.51 per share, with a total value of $400,392.90. Following the purchase, the director owned 9,041 shares in the company, valued at $1,297,473.91. This represents a 44.63% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 0.36% of the stock is owned by insiders.

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.